
    
      Multicentre, double-blind, randomised, placebo-controlled study in four parallel groups of PD
      patients treated with standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or
      levodopa/benserazide 100/25 mg (Madopar®/Restex®) and with motor fluctuations ("wearing-off"
      phenomenon)
    
  